M2GEN, an oncology-focused health informatics solutions company, today announced its participation as a presenter, exhibitor, and research partner at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition December 10th through 13th, 2022 in New Orleans, Louisiana.
Five poster presentations will be presented at ASH utilizing the rich longitudinal clinicogenomic data from M2GEN's Oncology Research Information Exchange Network (ORIEN) Avatar program, and showcase the collaboration of scientists across ORIEN, M2GEN, and other leading cancer centers across the nation. These projects highlight research discoveries in multiple myeloma and mantle cell lymphoma. Partnering with our 18 ORIEN members, M2GEN enables breakthrough scientific research to advance patient care.We look forward to meeting with colleagues, researchers, partners, and future clients individually and at our booth #3628 during the conference. To inquire about partnering with M2GEN and the Oncology Research Information Exchange Network (ORIEN), or to learn more about how our rich longitudinal clinicogenomic ORIEN Avatar® dataset could support your research efforts, contact info@M2GEN.com.
Learn more about how ORIEN investigators are collaborating with fellow Network members and M2GEN to leverage the expansive clinical and molecular Avatar database, for the research being featured at ASH 2022. The schedule of M2GEN supported poster presentations at ASH 2022 includes:
Saturday, December 10
Lymphoid Oncogenesis poster session
Rafael Renatino-Canevarolo, PhD, of H. Lee Moffitt Cancer Center & Research Institute will present a poster entitled “Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes” (Abstract: 1306, Full Text).
Multiple Myeloma and Plasma Cell Dyscrasias poster session
Praneeth Reddy Sudalagunta, PhD, of H. Lee Moffitt Cancer Center & Research Institute will present a poster entitled “A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data” (Abstract: 1848, Full Text).
Sunday, December 11
Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms poster session
Ryan T Bishop, PhD, of the H. Lee Moffitt Cancer Center & Research Institute will present a poster entitled “Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma” (Abstract: 2661, Full Text).
Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological poster session
David A. Bond, MD, BS, of Ohio State University will present a poster entitled “Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry” (Abstract: 2897, Full Text).
The abstract presented by Dr. Bond will feature research completed by seven ORIEN institutions working together to study relapse/refractory Non-Hodgkin’s lymphoma. This group is also a recipient of a Novel Oncologic Visionary Award (NOVA) from the ORIEN Foundation.
Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma oral program
Francesco Maura, MD, of Sylvester Comprehensive Cancer Center at University of Miami will present an oral presentation entitled “Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma” (Abstract: 646, Full Text).